Artificial Blood Institute

Revolutionizing Healthcare

Artificial Blood Institute in Boston

Follow Our Research Today >>>

Welcome to the Artificial Blood Institute

The Artificial Blood Institute has for its goal; the creation of a safe and effective artificial blood composition for transfusion into humans that is low in cost to produce and stable over extended periods of time. The Institute has developed a concept for the creation for such an artificial blood product and has recently filed several patent applications in the United States for this composition. The Institute intends to file additional patent applications worldwide as the concept is further developed. The Institute is publicly disclosing its artificial blood concept on this website and is seeking those involved in research, especially those involved in research on artificial blood and/or iron complexes of amino acids. to cooperate with the Institute in bringing such an artificial blood composition to commercialization. As an incentive to those involved in such research, if an individual or organization can demonstrate that it has such a commercially acceptable composition based upon the Institute’s concepts, the Institute will grant a world-wide license pursuant to the Institute’s patent holding to said individual or organization to make, use, sell and sublicense the artificial blood product for a license fee of 2.5% of net sales and 25% of royalty income, if any.

Want to know more?

Working to End Blood Shortages

Circumstances such as accidents, surgery, traumatic hemorrhagic shock, and other casualties cause major blood loss. Allogenic blood transfusion can be resuscitative for such conditions; however, it has numerous ambivalent effects, including supply shortage, needs for more time, cost for blood grouping, the possibility of spreading an infection, and short shelf-life. Hypoxia or ischemia causes heart failure, neurological problems, and organ damage in many patients. To address this emergent medical need for resuscitation and to treat hypoxic conditions as well as to enhance oxygen transportation, researchers aspire to achieve a robust technology with an object of developing safe and feasible blood substitutes, or artificial blood, for effective oxygen transport.

Talk to Us

How

It

Works

Artificial blood is designed to transport oxygen and carbon dioxide through the body. No substitutes have yet been invented that can replace the other vital functions of blood: coagulation and immune defense. Therefore, the replacement solutions being developed today are more accurately described as oxygen carriers. The most common oxygen carrier is based on hemoglobin. Hemoglobin is the protein in red blood cells that is responsible for carrying oxygen from the lung to the other tissues. Therefore, current methods to formulate blood substitutes are to use hemoglobin extracted from red blood cells. However, raw hemoglobin extracted from red blood cells cannot be used as a blood substitute. Each hemoglobin molecule is a tetramer that consists of four subunits. When infused into the body, a hemoglobin molecule breaks down into potentially toxic half molecules, or dimers. There are also other problems related to hemoglobin in free solution. The challenge to those engaged in research based upon hemoglobin is to modify the hemoglobin to allow it for use as a blood substitute.

Unraveling the Potential of Artificial Blood

Though efforts to develop an artificial blood based upon hemoglobin are in clinical trials, the required hemoglobin needed for the formulation of an artificial blood product relies upon using either native or recombinant human hemoglobin, modified forms of human hemoglobin or modified forms of hemoglobin from other species. Unmodified hemoglobin can be used as an oxygen therapeutic; however, it can bind NOx and causes severe vasoconstriction and hypertension. As a consequence of its molecular weight, hemoglobin can cause significant toxicities, especially to the kidney where it clogs the glomerular apparatus. As a consequence, the majority of tested hemoglobin in humans is modified to prolong their half-life and reduce their toxicity. Consequently, hemoglobin as an artificial blood is costly and difficult to acquire and store.

Connect Now

The Institute's Approach to Artificial Blood

Stay Informed and Inspired

The Artificial Blood Institute strives to keep you informed and engaged with groundbreaking articles. Visitors to this website are invited to submit their comments and any articles of interest. Check our website for updates as we delve into the fascinating world of artificial blood research. From breakthrough discoveries to innovative technologies, we'll deliver the latest updates submitted to us to your screen. Join us on this cutting-edge journey as we explore the endless possibilities of artificial blood. Get ready to be inspired, educated, and amazed.

Read Articles

Conclusion

The Andre Danesh Artificial Blood Institute is not seeking monetary benefit from the development of the artificial blood composition discussed above. Instead, it is offering any interested party the opportunity to participate in the development of such a product. Income generated by the Institute derived from its patent estate or other source of income will be used by the Institute to provide grants to those engaged in meaningful artificial blood research as determined by the Institute. Any interested party should feel free to contact the Institute using the contact information provided in this website.

Questions?

Get in Touch with us Today

We'd love to hear from you. Fill out the form below, and we'll be in touch as soon as possible.

Contact Us

Frequently Asked Questions

Have a question? We're here to help.